Implantable medical devices have a hard ceiling: the battery. Once a pacemaker, neurostimulator, or monitor is sealed and placed, its energy budget is fixed, and running out means a surgical replacement. One long-studied way around that ceiling is energy harvesting — converting the mechanical motion always present inside the body, such as the beating of the heart wall or the force of blood flow, into a trickle of electrical charge that tops up the cell. The engineering problem addressed by a patent issued to Medtronic on July 7, 2026 is not how to harvest that energy, but how the device can tell, from the inside, whether its own harvester is still working.

The patent, US12673210B2, “Energy harvesting system integrity monitoring,” is directed to a system with three cooperating parts: harvester circuitry that charges a battery using the displacement of a harvester mass, one or more accelerometers that detect the motion of that mass, and processing circuitry that reasons about the relationship between the two. The core idea is a cross-check. A harvester that is functioning normally should convert a given amount of mechanical motion into a predictable amount of electrical output. If the mass is clearly moving — the accelerometers say so — but the harvester output has quietly dropped, something in the harvesting mechanism has degraded.

A system includes harvester circuitry configured to charge a battery for a medical device using a displacement of a harvester mass, one or more accelerometers configured to detect a motion associated with the harvester mass, and processing circuitry. The processing circuitry is configured to determine, with the one or more accelerometers, motion information for the implanted medical device during a time range that occurs when the harvester circuitry charges the battery using the displacement of the harvester mass. The processing circuitry are further configured to determine a harvester output generated by the harvester circuitry during the time range and output an indication of a potential failure of the harvester mechanism based on the motion information and the harvester output.— Energy harvesting system integrity monitoring, US12673210B2

Reading motion against output

The mechanism the patent describes is deliberately concrete. The harvester mass is disclosed as translating heart-wall motion and blood-flow force into displacement, and the accelerometers measure the acceleration of that mass over a defined time range — specifically, a window that occurs while the harvester is charging the battery. To isolate the physiologically relevant motion from the broader jostling of daily activity, one dependent claim applies a band-pass filter over roughly 10 Hz to 30 Hz. The processing circuitry then forms a ratio between the harvester output and a count of accelerations, and compares that ratio against a threshold. In plain terms, it asks: for this much movement, am I getting the charge I should?

Because a single reading can be noisy, the patent also describes turning the comparison into a trend. It discloses computing a metric across multiple time ranges and fitting linear-regression polynomials over sets of those metrics, so the device tracks a slope rather than a snapshot. A harvester that is slowly losing efficiency shows up as a drift in that trend line before it becomes an outright failure, which is the kind of early signal a sealed implant otherwise has no way to surface.

What makes the independent claim more than a diagnostic is what the device does with the answer. Claim 1 ties the failure indication to an action: the processing circuitry is configured to modify the device's power usage based on the indication of a potential failure. The specification describes reducing power by turning off non-essential features. If the harvester can no longer be relied upon to replenish the cell, the device shifts to conserving what it has — extending the runway to a scheduled clinical follow-up rather than failing unexpectedly between visits.

Where it sits in the portfolio

The harvester-integrity patent lands within a same-week cohort of Medtronic grants that, read together, sketch a consistent theme: instrumenting implantable hardware so it can report on its own internal state and manage power accordingly. Adjacent to the harvesting work on the power side is US12676317B2, directed to over-discharge protection for the electrochemical cells that power implantable devices, using a lithophilic metal layer on the anode current collector. Together they address two ends of the same energy question — replenishing the cell and protecting it from damaging discharge.

Other grants in the cohort extend the instrumentation idea into different device families. US12672821B2 is directed to determining the efficacy of a treatment program through sensor-based response tracking, another instance of a device drawing conclusions from its own measurements. On the delivery and hardware side, US12673195B2 describes a separately positionable hemostasis valve for an implantable-lead introducer hub. And in Medtronic's MiniMed diabetes line, US12673159B2 is directed to mealtime delivery of correction boluses in automated insulin dosing, while US12673155B2 describes an insertion device with a linkage assembly for dual insertion of a cannula and a glucose sensor.

Viewed as an engineering document rather than a product announcement, the harvester-monitoring patent reflects a recurring constraint of implantable design: a device you cannot easily reach has to be its own technician. By reusing accelerometers — sensors already common in modern implants — to audit the harvester rather than adding dedicated failure hardware, the disclosed approach keeps the self-diagnostic lightweight, and folds the result straight into how the device rations its remaining energy.